{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:27:37Z","timestamp":1787236057047,"version":"build-2736575974"},"reference-count":32,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002378"],"award-info":[{"award-number":["UL1TR002378"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["TL1TR002382"],"award-info":[{"award-number":["TL1TR002382"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"award":["UL1TR002378"],"award-info":[{"award-number":["UL1TR002378"]}],"id":[{"id":"https:\/\/ror.org\/04pw6fb54","id-type":"ROR","asserted-by":"publisher"}]},{"award":["TL1TR002382"],"award-info":[{"award-number":["TL1TR002382"]}],"id":[{"id":"https:\/\/ror.org\/04pw6fb54","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are transforming obesity management, yet landmark trials often incompletely measure and report a central mediator of response: dietary intake. Because GLP-1RAs promote weight loss primarily by suppressing appetite and reducing energy consumption, capturing changes in dietary intake is essential to interpreting efficacy, safety, and translation into clinical care. This perspective argues that failure to measure and report comprehensive dietary intake raises concerns under four core bioethical principles. It undermines autonomy by limiting evidence for shared decision-making across the treatment continuum. It challenges non-maleficence because inadequate energy, protein, and micronutrient intake may contribute to lean mass loss and nutrient deficiencies, particularly in vulnerable populations. It weakens beneficence because failing to report a measurable mediator diminishes the scientific value of research requiring substantial investment and participant burden. It raises justice concerns because the equitable distribution of assessment burden and access to resulting nutritional care cannot be evaluated without transparent reporting. To meet the ethical and scientific obligations of clinical research, future trials should preregister dietary intake as a key secondary or safety endpoint. Investigators should report total energy, macronutrient, and micronutrient distribution at baseline and serial follow-up alongside dietary assessment methods, food composition databases, and assessor training. Journal editors, funders, and regulatory bodies should support development of consensus-based, nutrition-specific reporting recommendations aligned with CONSORT principles and encourage preregistration of dietary trial endpoints. Registered dietitian nutritionists should be prospectively integrated into GLP-1RA trial teams from design through data interpretation. Advancing the standard of obesity care requires that the research community look beyond the scale and ground clinical translation in the nutritional context in which pharmacotherapy operates.<\/jats:p>","DOI":"10.3390\/nu18162722","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T09:48:31Z","timestamp":1787219311000},"page":"2722","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dietary Intake as an Undermeasured Potential Mediator: The Ethical Case for Complete and Transparent Dietary Reporting in GLP-1 Receptor Agonist Trials"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7821-7034","authenticated-orcid":false,"given":"Jessica N.","family":"Strosahl","sequence":"first","affiliation":[{"name":"Department of Human Genetics, Emory University, Atlanta, GA 30322, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Ziegler","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Metabolism and Lipids, Emory University, Atlanta, GA 30322, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2096-2592","authenticated-orcid":false,"given":"Rani H.","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Human Genetics, Emory University, Atlanta, GA 30322, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-Weekly Semaglutide in Adults with Overweight or Obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide Once Weekly for the Treatment of Obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management","volume":"373","author":"Astrup","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e70077","DOI":"10.1111\/obr.70077","article-title":"A Systematic Review Identifying Critical Evidence Gaps in Reporting Dietary Change in Randomized Controlled Trials Prescribing Liraglutide, Semaglutide, or Tirzepatide","volume":"27","author":"Jansson","year":"2026","journal-title":"Obes. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"100491","DOI":"10.1016\/j.advnut.2025.100491","article-title":"Examining the Omission of Dietary Quality Data in Glucagon-Like Peptide 1 Clinical Trials: A Scoping Review","volume":"16","author":"Babazadeh","year":"2025","journal-title":"Adv. Nutr."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"156113","DOI":"10.1016\/j.metabol.2024.156113","article-title":"Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis","volume":"164","author":"Karakasis","year":"2025","journal-title":"Metabolism"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/dom.15728","article-title":"Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies","volume":"26","author":"Neeland","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1001\/jama.2025.24288","article-title":"World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults","volume":"335","author":"Celletti","year":"2026","journal-title":"JAMA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"100498","DOI":"10.1016\/j.advnut.2025.100498","article-title":"The Silent Weight of Nutrition Data in Glucagon-Like Peptide-1 Receptor Agonists Clinical Trials","volume":"16","author":"Dashti","year":"2025","journal-title":"Adv. Nutr."},{"key":"ref_11","unstructured":"Beauchamp, T.L., and Childress, J.F. (1979). Principles of Biomedical Ethics, Oxford University Press."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"101351","DOI":"10.1016\/j.molmet.2021.101351","article-title":"GLP-1 physiology informs the pharmacotherapy of obesity","volume":"57","author":"Drucker","year":"2022","journal-title":"Mol. Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"E401","DOI":"10.1152\/ajpendo.00480.2024","article-title":"Semaglutide mitigates the loss of fat-free mass and decreased energy expenditure observed after diet restriction. Insights from an obese minipig model","volume":"330","author":"Bredum","year":"2026","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Ma, T., Song, F., Pan, Y., He, Y., Cao, X., Zhang, Y., Song, G., and Ren, L. (2025). Distinct effects of semaglutide and tirzepatide on metabolic and inflammatory gene expression in brown adipose tissue of mice fed a high-fat, high-fructose diet. Front. Nutr., 12.","DOI":"10.3389\/fnut.2025.1659233"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Hropot, T., Herman, R., Janez, A., Lezaic, L., and Jensterle, M. (2023). Brown Adipose Tissue: A New Potential Target for Glucagon-like Peptide 1 Receptor Agonists in the Treatment of Obesity. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24108592"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"World Medical Association (2025). World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Participants. JAMA, 333, 71\u201374.","DOI":"10.1001\/jama.2024.21972"},{"key":"ref_17","unstructured":"International Committee of Medical Journal Editors (2026, May 28). Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals. Available online: https:\/\/www.icmje.org\/recommendations\/."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e13929","DOI":"10.1111\/obr.13929","article-title":"Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis","volume":"26","author":"Berg","year":"2025","journal-title":"Obes. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e085304","DOI":"10.1136\/bmj-2025-085304","article-title":"Weight regain after cessation of medication for weight management: Systematic review and meta-analysis","volume":"392","author":"West","year":"2026","journal-title":"BMJ"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"102475","DOI":"10.1016\/j.eclinm.2024.102475","article-title":"Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: A post-treatment analysis of a randomised placebo-controlled trial","volume":"69","author":"Jensen","year":"2024","journal-title":"EClinicalMedicine"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/dom.16012","article-title":"Characterizing body composition modifying effects of a glucagon-like peptide 1 receptor-based agonist: A meta-analysis","volume":"27","author":"Jiao","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/sj.ijo.0803483","article-title":"Changes in fat-free mass during significant weight loss: A systematic review","volume":"31","author":"Chaston","year":"2007","journal-title":"Int. J. Obes."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12966-024-01657-9","article-title":"Comparing caloric restriction regimens for effective weight management in adults: A systematic review and network meta-analysis","volume":"21","author":"Huang","year":"2024","journal-title":"Int. J. Behav. Nutr. Phys. Act."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"bvae164","DOI":"10.1210\/jendso\/bvae164","article-title":"Fundamental Body Composition Principles Provide Context for Fat-Free and Skeletal Muscle Loss with GLP-1 RA Treatments","volume":"8","author":"Tinsley","year":"2024","journal-title":"J. Endocr. Soc."},{"key":"ref_25","first-page":"109123","article-title":"Saving muscle while losing weight: A vital strategy for sustainable results while on glucagon-like peptide-1 related drugs","volume":"16","author":"Ruzic","year":"2025","journal-title":"World J. Diabetes"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e13841","DOI":"10.1111\/obr.13841","article-title":"Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity","volume":"26","author":"Mechanick","year":"2025","journal-title":"Obes. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Al-Najim, W., Raposo, A., BinMowyna, M.N., and le Roux, C.W. (2025). Unintended Consequences of Obesity Pharmacotherapy: A Nutritional Approach to Ensuring Better Patient Outcomes. Nutrients, 17.","DOI":"10.3390\/nu17111934"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e51432","DOI":"10.2196\/51432","article-title":"Advancements in Using AI for Dietary Assessment Based on Food Images: Scoping Review","volume":"26","author":"Chotwanvirat","year":"2024","journal-title":"J. Med. Internet Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.copbio.2021.02.007","article-title":"Overview of dietary assessment methods for measuring intakes of foods, beverages, and dietary supplements in research studies","volume":"70","author":"Bailey","year":"2021","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1007\/s00394-023-03137-5","article-title":"Perspectives on the application of CONSORT guidelines to randomised controlled trials in nutrition","volume":"62","author":"Ahles","year":"2023","journal-title":"Eur. J. Nutr."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s43016-024-01089-5","article-title":"Predictive equation derived from 6,497 doubly labelled water measurements enables the detection of erroneous self-reported energy intake","volume":"6","author":"Bajunaid","year":"2025","journal-title":"Nat. Food"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1093\/aje\/kwac026","article-title":"Measurement Error Affecting Web- and Paper-Based Dietary Assessment Instruments: Insights From the Multi-Cohort Eating and Activity Study for Understanding Reporting Error","volume":"191","author":"Kirkpatrick","year":"2022","journal-title":"Am. J. Epidemiol."}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/18\/16\/2722\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T09:58:34Z","timestamp":1787219914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/18\/16\/2722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":32,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["nu18162722"],"URL":"https:\/\/doi.org\/10.3390\/nu18162722","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]}}}